For lung cancer patients, getting an earlier diagnosis is crucial in creating the opportunity for accelerating treatment discussions – every minute matters.

Johnson & Johnson is striving toward improving outcomes for patients with lung cancer. To do that, we are innovating to revolutionize how pulmonary diseases, including lung cancer, is diagnosed with technology that can help physicians diagnose the disease earlier, as well as solutions that could treat it with precision1.

Our MONARCH™ Platform, a robotically assisted bronchoscopy system, improves how physicians reach and biopsy lung lesions in the periphery of the lung2 compared to traditional bronchoscopes. The MONARCH™ Bronchoscope is designed for continuous vision throughout the procedure.3*†. It is designed to travel through the airways deep into the lungs and guide a biopsy instrument into even the most difficult to reach nodules, while maintaining vision during the most critical segment of the procedure, the
biopsy4‡.

Learn more about The MONARCH™ Platform – https://www.jnjmedtech.com/en-US/product/monarch-bronchoscopy
Learn more about J&J’s Mission to improve lung cancer outcomes. https://www.jnj.com/tag/lung-cancer

References
* MONARCH Platform System Design Verification Report B2.0, Dec. 2019
† AURIS Bronch 2.0 DVAL Report- Functionality, Dec. 2019
‡ MONARCH Platform User Manual – Bronch 2.0, 300-011197-00, Dec. 2021
1. “Lung cancer wasn’t even on my radar. Then I was diagnosed.” JNJ.com. Published June 4, 2024. Accessed July 16, 2024. https://www.jnj.com/personalstories/lung-cancer-diagnosis-wasnt-on-radar
2. Retrospective Chart Review of Monarch Diagnostic Bronchoscopy Outcomes in Real-world Clinical Practice
3. AURIS, 104-002610-01 MONARCH Platform Design Verification Report B2.0, Dec. 2019, pgs. 18-19
4. AURIS, 104-002610-01 MONARCH Platform System Design Verification Report B2.0, Dec. 2019, Validation Test Report.

US_ETH_RADS_387080 | © 2024 Ethicon Inc. All rights reserved.